ONCAlert | Upfront Therapy for mRCC
Videos  >  

Expert Addresses Sequencing Challenges in HCC

Kabir Mody, MD
Published Online:8:29 PM, Fri December 21, 2018

Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses the importance of understanding sequencing in patients with hepatocellular carcinoma (HCC).

This is a new era in HCC with regard to the amount of treatment options patients have, Mody says. The question now is how these agents should be sequenced.

There is not much data available yet, but some second-line trials have looked at patients who have progressed on sorafenib (Nexavar) to determine which agent can be used next. The CheckMate040 study also had a cohort of patients who had no prior systemic therapy prior to treatment with nivolumab (Opdivo). There are also a few first-line trials pending looking at immunotherapies.

Mody says more work still needs to be done in terms of sequencing these agents.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.